Alexander Dela Llana, MD
Family Medicine · Evansville, INNPI 1790771848
Payments from drug & device makers
Across 522 payments — averaging $3073.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$486K
- Novo Nordisk AS$339K
- Astrazeneca UK Limited$228K
- AbbVie$157K
- Teva Pharmaceuticals USA, Inc.$116K
- Acadia Pharmaceuticals Inc$86K
- plus $192K from 22 others
What the payments were for
- Food & beverage$54899%
- Education$61%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 49 | $486,000 |
| Novo Nordisk AS | 254 | $338,720 |
| Astrazeneca UK Limited | 3 | $228,455 |
| AbbVie(2 entities) | 87 | $156,553 |
| Teva Pharmaceuticals USA, Inc. | 37 | $116,036 |
| Acadia Pharmaceuticals Inc | 17 | $85,882 |
| AstraZeneca | 10 | $63,072 |
| Amgen(2 entities) | 6 | $61,016 |
| Shire North American Group Inc | 13 | $31,440 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $27,507 |
| Novartis | 1 | $4,989 |
| Adare Pharmaceuticals, Inc. | 4 | $3,772 |
| Seres Therapeutics, Inc. | 1 | $350 |
| Sanofi-aventis U.S. LLC | 3 | $39 |
| Novo Nordisk | 3 | $38 |
| Boehringer Ingelheim | 3 | $34 |
| Genentech USA, Inc. | 2 | $29 |
| Pfizer | 2 | $27 |
| Edwards Lifesciences | 1 | $26 |
| Astellas Pharma US Inc | 2 | $24 |
| Lilly USA, LLC | 2 | $23 |
| Bausch Health US, LLC | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| Supernus Pharmaceuticals, Inc. | 1 | $12 |
| GSK | 1 | $12 |
| Kowa Pharmaceuticals America, Inc. | 1 | $11 |
How this compares
$1,604,132 in reported general payments places this provider in the 95th percentile of 2,709 family medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 81 | $115,167 |
| EliquisApixaban | 114 | $102,365 |
| XareltoRivaroxaban | 61 | $55,973 |
| JardianceEmpagliflozin | 37 | $33,364 |
| MounjaroTirzepatide | 29 | $30,145 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 34 | $27,569 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $24,656 |
| Aimovig AutoinjectorErenumab-Aooe | 19 | $21,217 |
| GemtesaVibegron | 17 | $17,822 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $16,349 |
| MyrbetriqMirabegron | 22 | $15,940 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 16 | $13,953 |
| Semglee (Yfgn) PenInsulin Glargine-Yfgn | 30 | $12,654 |
| SymbicortBudesonide/Formoterol Fumarate | 24 | $10,679 |
| Humalog Kwikpen U-100Insulin Lispro | 32 | $8,694 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $38 | $115,16781 claims |
| PfizerEliquis | $27 | $102,365114 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $34 | $47,31653 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $12 | $43,91853 claims |
| Lilly USA, LLCMounjaro | $23 | $30,14529 claims |
| AstraZenecaSymbicort, Farxiga, Breztri Aerosphere | $63,072 | $26,57848 claims |
| Astellas Pharma US IncMyrbetriq | $24 | $15,94022 claims |
| AbbVieSynthroid | $156,553 | $3,99648 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Evansville
- J Christopher SartoreEvansville$3.9M
- Hubert ReyesEvansville$3.2M
- David SchultzEvansville$3M
- David BrougherEvansville$556K
- Anthony InzerelloEvansville$338K
- James GutmannEvansville$311K
- Randall StoltzEvansville$248K
- William SmithEvansville$150K
- Carol GoodmanEvansville$123K
- Lauren VeazeyEvansville$71K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.